SG11202105769XA - Inhibitors of apol1 and methods of using same - Google Patents
Inhibitors of apol1 and methods of using sameInfo
- Publication number
- SG11202105769XA SG11202105769XA SG11202105769XA SG11202105769XA SG11202105769XA SG 11202105769X A SG11202105769X A SG 11202105769XA SG 11202105769X A SG11202105769X A SG 11202105769XA SG 11202105769X A SG11202105769X A SG 11202105769XA SG 11202105769X A SG11202105769X A SG 11202105769XA
- Authority
- SG
- Singapore
- Prior art keywords
- apol1
- inhibitors
- methods
- same
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/46—Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780667P | 2018-12-17 | 2018-12-17 | |
| PCT/US2019/066746 WO2020131807A1 (en) | 2018-12-17 | 2019-12-17 | Inhibitors of apol1 and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105769XA true SG11202105769XA (en) | 2021-07-29 |
Family
ID=69182627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105769XA SG11202105769XA (en) | 2018-12-17 | 2019-12-17 | Inhibitors of apol1 and methods of using same |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11618746B2 (he) |
| EP (1) | EP3897833A1 (he) |
| JP (1) | JP7573528B2 (he) |
| KR (1) | KR20210116483A (he) |
| CN (1) | CN113453760B (he) |
| AR (1) | AR116913A1 (he) |
| AU (1) | AU2019405477A1 (he) |
| BR (1) | BR112021011564A2 (he) |
| CA (1) | CA3121910A1 (he) |
| CL (1) | CL2021001561A1 (he) |
| CO (1) | CO2021009053A2 (he) |
| CR (1) | CR20210383A (he) |
| DO (1) | DOP2021000116A (he) |
| EC (1) | ECSP21052184A (he) |
| IL (1) | IL283592A (he) |
| JO (3) | JOP20210130A1 (he) |
| MA (1) | MA54538A (he) |
| MX (1) | MX2021007152A (he) |
| PE (1) | PE20212302A1 (he) |
| SA (1) | SA521422270B1 (he) |
| SG (1) | SG11202105769XA (he) |
| TW (1) | TWI848031B (he) |
| UA (1) | UA128375C2 (he) |
| UY (1) | UY38514A (he) |
| WO (1) | WO2020131807A1 (he) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7573528B2 (ja) | 2018-12-17 | 2024-10-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｐｏｌ１の阻害剤及びその使用方法 |
| EP4097083A1 (en) * | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| EP4114385A1 (en) | 2020-03-06 | 2023-01-11 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CN115867543A (zh) * | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| KR20230057386A (ko) * | 2020-08-26 | 2023-04-28 | 버텍스 파마슈티칼스 인코포레이티드 | Apol1 억제제 및 사용 방법 |
| JP2024532272A (ja) * | 2021-08-26 | 2024-09-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | 固体型のスピロ三環式ａｐｏｌ１阻害剤およびその使用方法 |
| CN118632850A (zh) * | 2021-11-30 | 2024-09-10 | 弗特克斯药品有限公司 | Apol1的螺环抑制剂和其使用方法 |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| WO2023154344A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
| WO2024040235A1 (en) * | 2022-08-19 | 2024-02-22 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| CA2262569A1 (en) | 1996-08-09 | 1998-02-19 | Norihito Ohi | Benzopiperidine derivatives |
| WO1999032112A1 (en) | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Method for treating diabetes |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU7514700A (en) | 1999-09-07 | 2001-04-10 | Syngenta Participations Ag | Cyanopiperidines |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| JP2004510762A (ja) | 2000-10-02 | 2004-04-08 | メルク エンド カムパニー インコーポレーテッド | プレニル−蛋白質トランスフェラーゼの阻害剤 |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| CN1612866A (zh) | 2001-11-14 | 2005-05-04 | 特瓦制药工业有限公司 | 无定形和结晶形的氯沙坦钾及其制备方法 |
| WO2003104180A1 (en) * | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| AU2003301020A1 (en) | 2002-12-20 | 2004-07-22 | Sankyo Company, Limited | Isoquinolinone derivatives and their use as therapeutic agents |
| AU2004268919A1 (en) | 2003-09-03 | 2005-03-10 | Galapagos Nv | Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders |
| CN1926104A (zh) | 2004-03-03 | 2007-03-07 | 伊莱利利公司 | 作为类固醇激素核受体调节剂的双环取代的吲哚衍生物 |
| AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CA2666406A1 (en) | 2006-10-16 | 2008-04-24 | Gruenenthal Gmbh | Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators |
| AU2007338115A1 (en) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| SI2118074T1 (sl) * | 2007-02-01 | 2014-05-30 | Resverlogix Corp. | Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| KR20090018593A (ko) | 2007-08-17 | 2009-02-20 | 주식회사 엘지생명과학 | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 |
| BRPI1015097A2 (pt) | 2009-05-29 | 2019-09-24 | Raqualia Pharma Inc | uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo. |
| PT2501704E (pt) | 2009-11-16 | 2013-12-05 | Lilly Co Eli | Compostos de espiropiperidina como antagonistas do receptor orl-1 |
| UA107943C2 (en) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Compounds of spiropiperidines as antagonists of the orl-1 receptors |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| WO2014085154A1 (en) | 2012-11-27 | 2014-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| US10377711B2 (en) | 2014-08-27 | 2019-08-13 | The University Court Of The University Of Aberdeen | Cannabinoid type 1 receptor modulators |
| JP2017536342A (ja) | 2014-10-08 | 2017-12-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物 |
| CN107001369A (zh) | 2014-11-21 | 2017-08-01 | 埃斯蒂文博士实验室股份有限公司 | 针对疼痛具有多模式活性的螺‑异喹啉‑1,4’‑哌啶化合物 |
| BR112018001650A2 (pt) | 2015-08-27 | 2018-09-18 | Pfizer | compostos de heteroarila ou arila fundidos bicíclicos como moduladores de irak4 |
| JP6990657B2 (ja) | 2016-02-08 | 2022-01-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｄｄｒ１阻害剤としてのスピロインドリノン |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| PE20211397A1 (es) | 2018-05-22 | 2021-07-27 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de apol1 |
| JP7573528B2 (ja) | 2018-12-17 | 2024-10-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｐｏｌ１の阻害剤及びその使用方法 |
| US20220144838A1 (en) | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| EP4076423A4 (en) | 2019-12-19 | 2024-03-13 | Casma Therapeutics, Inc. | TRPML MODULATORS |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| EP4114385A1 (en) * | 2020-03-06 | 2023-01-11 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| WO2021216665A1 (en) | 2020-04-22 | 2021-10-28 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
| IL297849A (he) | 2020-05-07 | 2023-01-01 | Rambam Med Tech Ltd | הרכב לשימוש בטיפול במחלה הקשורה ל- apol1 |
| EP4165023A1 (en) | 2020-06-12 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| WO2021252859A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| KR20230057386A (ko) | 2020-08-26 | 2023-04-28 | 버텍스 파마슈티칼스 인코포레이티드 | Apol1 억제제 및 사용 방법 |
| JP2024532272A (ja) | 2021-08-26 | 2024-09-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | 固体型のスピロ三環式ａｐｏｌ１阻害剤およびその使用方法 |
| US20230203000A1 (en) | 2021-11-30 | 2023-06-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| CN118632850A (zh) | 2021-11-30 | 2024-09-10 | 弗特克斯药品有限公司 | Apol1的螺环抑制剂和其使用方法 |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| WO2023154314A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Spiro piperidine derivatives as inhibitors of apol1 and methods of using same |
| WO2023154344A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| WO2023154309A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
-
2019
- 2019-12-17 JP JP2021534284A patent/JP7573528B2/ja active Active
- 2019-12-17 JO JOP/2021/0130A patent/JOP20210130A1/ar unknown
- 2019-12-17 MA MA054538A patent/MA54538A/fr unknown
- 2019-12-17 AR ARP190103717A patent/AR116913A1/es unknown
- 2019-12-17 SG SG11202105769XA patent/SG11202105769XA/en unknown
- 2019-12-17 JO JOP/2021/0131A patent/JOP20210131A1/ar unknown
- 2019-12-17 CR CR20210383A patent/CR20210383A/es unknown
- 2019-12-17 US US16/717,099 patent/US11618746B2/en active Active
- 2019-12-17 TW TW108146307A patent/TWI848031B/zh active
- 2019-12-17 CA CA3121910A patent/CA3121910A1/en active Pending
- 2019-12-17 JO JOP/2021/0129A patent/JOP20210129A1/ar unknown
- 2019-12-17 PE PE2021000896A patent/PE20212302A1/es unknown
- 2019-12-17 BR BR112021011564-1A patent/BR112021011564A2/pt not_active Application Discontinuation
- 2019-12-17 CN CN201980092356.3A patent/CN113453760B/zh active Active
- 2019-12-17 EP EP19839496.7A patent/EP3897833A1/en active Pending
- 2019-12-17 WO PCT/US2019/066746 patent/WO2020131807A1/en active Application Filing
- 2019-12-17 MX MX2021007152A patent/MX2021007152A/es unknown
- 2019-12-17 UA UAA202104153A patent/UA128375C2/uk unknown
- 2019-12-17 KR KR1020217022550A patent/KR20210116483A/ko unknown
- 2019-12-17 UY UY0001038514A patent/UY38514A/es unknown
- 2019-12-17 AU AU2019405477A patent/AU2019405477A1/en active Pending
-
2021
- 2021-05-31 IL IL283592A patent/IL283592A/he unknown
- 2021-06-15 SA SA521422270A patent/SA521422270B1/ar unknown
- 2021-06-15 DO DO2021000116A patent/DOP2021000116A/es unknown
- 2021-06-15 CL CL2021001561A patent/CL2021001561A1/es unknown
- 2021-07-09 CO CONC2021/0009053A patent/CO2021009053A2/es unknown
- 2021-07-15 EC ECSENADI202152184A patent/ECSP21052184A/es unknown
-
2023
- 2023-02-07 US US18/106,569 patent/US12060346B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL283592A (he) | 2021-07-29 |
| CN113453760B (zh) | 2024-05-24 |
| CN113453760A (zh) | 2021-09-28 |
| CA3121910A1 (en) | 2020-06-25 |
| CO2021009053A2 (es) | 2021-08-09 |
| WO2020131807A1 (en) | 2020-06-25 |
| US20230271945A1 (en) | 2023-08-31 |
| PE20212302A1 (es) | 2021-12-10 |
| EP3897833A1 (en) | 2021-10-27 |
| US11618746B2 (en) | 2023-04-04 |
| UY38514A (es) | 2020-07-31 |
| CR20210383A (es) | 2021-09-22 |
| JP7573528B2 (ja) | 2024-10-25 |
| US12060346B2 (en) | 2024-08-13 |
| JP2022515369A (ja) | 2022-02-18 |
| CL2021001561A1 (es) | 2021-11-26 |
| DOP2021000116A (es) | 2021-09-30 |
| AR116913A1 (es) | 2021-06-23 |
| US20200377479A1 (en) | 2020-12-03 |
| MX2021007152A (es) | 2021-11-03 |
| SA521422270B1 (ar) | 2024-02-18 |
| JOP20210130A1 (ar) | 2023-01-30 |
| TWI848031B (zh) | 2024-07-11 |
| BR112021011564A2 (pt) | 2021-08-31 |
| JOP20210131A1 (ar) | 2023-01-30 |
| AU2019405477A1 (en) | 2021-06-24 |
| TW202039471A (zh) | 2020-11-01 |
| UA128375C2 (uk) | 2024-06-26 |
| JOP20210129A1 (ar) | 2023-01-30 |
| KR20210116483A (ko) | 2021-09-27 |
| MA54538A (fr) | 2021-10-27 |
| ECSP21052184A (es) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283592A (he) | מעכבי apol1 ושיטות שימוש בהם | |
| EP3700527A4 (en) | PAPD5 INHIBITORS AND THEIR METHODS OF USE | |
| EP3684361A4 (en) | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE | |
| IL287751A (he) | מעכבי kcnt1 ושיטות לשימוש | |
| IL279475A (he) | מעכבי אקטונוקליאוטידאז ושיטות לשימוש בהם | |
| IL287768A (he) | מעכבי kcnt1 ושיטות לשימוש | |
| IL276711A (he) | מעכבי ארגינז ושיטות השימוש בהם | |
| IL287973A (he) | מעכבי acss2 ושיטות לשימושם | |
| IL278989A (he) | מדכאי masp-2 ושיטות לשימוש בהם | |
| IL274504A (he) | מעכבי 2acss ושיטות לשימושם | |
| EP3735242A4 (en) | METALLO-BETA-LACTAMASE INHIBITORS AND THEIR METHODS OF USE | |
| EP3706737A4 (en) | ASH11 INHIBITORS AND METHOD OF TREATING THEREOF | |
| EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| IL280924A (he) | מעכבי ארגינאס ושיטות לשימוש בהם | |
| IL286485A (he) | מעכבי pi4-קיינאס ושיטות לשימוש בהן | |
| EP3615532A4 (en) | TRIM33 INHIBITORS AND METHOD OF USE | |
| IL276053A (he) | Gard טיפולי ושיטות לשימוש שלו | |
| IL286149A (he) | מעכבי caspase ושיטות שימוש בהם | |
| EP3793552C0 (en) | ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF | |
| IL289127A (he) | מעכבי ppm1a ושיטות לשימוש בהם | |
| EP3968994C0 (en) | ABHD12 INHIBITORS AND METHODS FOR THE PRODUCTION AND USE THEREOF | |
| EP3654968A4 (en) | METALLO BETA LACTAMASE INHIBITORS AND METHOD OF USING THEM |